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Abstract: 
The emerging domain of epigenetics in molecular medicine finds application for a variety of patient populations. Here, we 
present fundamental neuroendocrine immune evidence obtained in patients with senile dementia of the Alzheimer’s type (sDAT), 
and discuss the implications of these data from the viewpoint of translational epigenetics of Alzheimer’s disease. We followed 18 
subjects with mild sDAT treated with acetylcholinesterase inhibitors, and 10 control subjects matched for age in a repeated 
measure design every six months for 18 months. We monitored psychosocial profile (Mini-Mental State Examination, Functional 
Assessment Staging, Independence in Activities of Daily Living, Depression, Profile of Moods States) in parallel to 
immunophenotypic parameters of T cell subpopulations by flow cytometry. Based on change in the mini-mental state score at 
entry and at 18 months, patients with sDAT were assigned to a “fast progression” (delta greater than 2 points) or to a “slow 
progression” group (delta less than or equal to 2 points). The change in circulating activated T cells (CD3+Dr+) with time in 
patients with sDAT was significantly inversely correlated with the change in time in natural killer (NK) cytotoxic activity to 
cortisol modulation in these patients, which was greater in patients with fast progression, compared to slow progression sDAT. 
These data indicate underlying neuroendocrine immune processes during progression of sDAT. Our observations suggest that 
psychoimmune measures such as those we have monitored in this study provide relevant information about the evolving 
physiological modulation in patients with sDAT during progression of Alzheimer’s disease, and point to new or improved 
translational epigenetic treatment interventions. 
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Background:  
Epigenetics refers to the domain of study of the molecular 
factors in the organism that modulate its adaptation to 
environment and intrinsic demands. [1] Epigenetic processes 
work in concert to enhance and to optimize physiological 
homeostasis and allostasis, the adaptation of the organisms 
following stress or pathologies. Molecular cartography, 
including genomics, proteomics, and interactomics, seeks to 
recognize and to identify the multi-faceted and intricate array 
of interacting genes and gene products that characterize the 
function and specialization of each individual cell in the 
context of cell-cell interaction, tissue, and organ function. 
Molecular epigenetics refers to the study of non-coding vs. 
coding DNA, and pertains to every domain of physiology, 
including the regulation of cellular immunity by specific T 
cell subpopulations (e.g., regulatory T cells, Tregs, 
CD4+CD25+FoxP3+ [2]), and the interaction between the 
immune and the neuroendocrine systems. [3] 
 
Alzheimer's disease, a progressive neuro-degenerative disease 
caused in part by the deposit of the β amyloid protein, is the 
fastest growing type of senile dementia. It is estimated that 
within the present decade, over five million people will be 
diagnosed with senile dementia of the Alzheimer’s type 
(sDAT) in the US alone. Current treatment interventions 
include acetylcholinesterase inhibitors (e.g., Donezepil, 
[Aricept®]). [4-6]  
 
Clinical observations indicate that patients with sDAT 
manifest marked immune disorders, which tend to worsen as 
the dementia progresses.  Research data confirm this body of 
evidence, and indicate significantly impaired cell-mediated 
immune regulation, which appears to be on the one hand 
associated with altered T cell-mediated immunity [3, 7], and 
on the other to be correlated with the severity of sDAT. [8, 9] 
Therefore, we tested the hypothesis that changes in the profile 
of circulating T cells is associated with neuroendocrine 
modulation of cellular immune function in these patients, and 
can have clinically relevant applicability as a prognostic 
factor of sDAT.  The implications of our work pertains to the 
development of new and improved modes of treatment 
intervention for patients with sDAT that recognize and 
identify the multi-faceted and intricate array of both coding 
and non-coding DNA domains and gene products during the 
progression of Alzheimer’s disease. 
 
Description: A longitudinal prospective cohort study was 
designed to address the clinical applicability of physiologic 
modulation of cellular immune phenotypic and functional 
markers as prognostic factors of sDAT progression. In a 
repeated measure design, we followed 18 subjects (age range 
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from 61 to 84 years old) with mild sDAT under treatment 
with acetylcholinesterase inhibitors (Donezepil 10 mg per 
day), and 10 healthy control subjects (59 to 84 years of age). 
Patients were selected on the basis of short history of disease 
and no medication at baseline. Psychoimmune measures were 
obtained at entry and at six months intervals for 18 months. 
 
At each visit, patients underwent a battery of psychometric 
tests [Mini-Mental State Examination (MMSE); Mini-Mental 
State Examination-age and education corrected (MMSE-C); 
Functional Assessment Staging (FAST); index of 
Independence in Activities of Daily Living (ADL); Center for 
Epidemiology Studies–Depression (CES-D); Profile of 
Moods States (POMS)] to evaluate their cognitive 
performance and their psychological status. Based on change 
in the MMSE score at entry and at 18 months follow-up, 
patients with sDAT were assigned to a “fast progression” (Δ 
> 2 points; n = 8, two men, six women) or to a “slow 
progression” group (Δ < 2 points; (n = 10; two men, eight 
women). 
 
We also examined in parallel immunophenotypic parameters 
of T cells by dual fluorescence flow cytometry. In brief, at 
each visit we obtained peripheral blood from an antecubital 
vein with ethylene diamine tetra-acetic acid (EDTA) as 
anticoagulant. Samples were collected between 0800 and 
1000 hours, and the participants were instructed to take no 
food, caffeine, or nicotine for at least 1 hour prior to sample 
collection to minimize circadian and neuroendocrine-induced 
variability in immune measurements. Blood count (wbc) and 
differential were obtained, and the samples were centrifuged 
(1500 rpm, room temp, 10 min). Serum aliquots were 
cryopreserved at -70°C, and a fraction of the buffy coats used 
for whole blood flow cytometry. Flow cytometric data were 
analyzed by transforming the percent data produced by the 
flow analysis to absolute numbers using WBC and 
differential. [3] Flow cytometric data are presented in Table 1 
(see supplementary material). 
 
The remainder of the buffy coats was used for separation of 
peripheral blood mononuclear cells (PBMC) by standard 
buoyant density centrifugation. PBMC were tested for natural 
killer (NK) cytotoxicity of the human myeloblastoma cell line 
K562 target in the presence or the absence of the either 
negative (cortisol [Sigma, St. Louis, MO], micro M) or 
positive NK modulators (human recombinant IL-2 
[Eurocetus, Emeryville, CA], 100 IU per ml). NK cytotoxic 
activity was measured by the non-radiometric direct 
colorimetric 4-h assay, by assessing the concentration of 
lactate dehydrogenase (LDH) released by the lysed cells, and 
expressed as lytic units (LU) per 10 million cells. [10-14] NK 
modulation data are presented in Table 2 under 
supplementary material (note: the data in were published as 
original findings [14], and are presented here for reference 
purpose only.). 
 
Data were expressed as means + standard deviation (SD), or 
standard error of the mean (SEM), as indicated. Parametric 
tests were used only when the data verified the three 
assumptions of normal distribution, independence of 
measurements and homogeneity of variance. Statistical 
significance of differences in the values of immune phenotype 
or function was determined by Student’s t-test (or Wilcoxon’s 
rank sign test). Repeated measure ANOVA (or Friedmann) 
was used to analyze the longitudinal data. Statistical analysis 
was performed at a level of significance α = 0.10 because of 
the variability accounted for by individual differences 
(Statistix [NIH Analytical Software, USA], Analyze-It, 
version 1.72 [Analyze-It Software, Ltd.]). [14] 
 
Based on the change in MMSE from baseline, patients with 
sDAT were assigned to a “fast progression” group if the score 
Δ was greater than 2 points, or a “slow progression” group if 
the score Δ was less than or equal to 2 points. Patients with 
Fast Progression sDAT exhibited a significant drop in score 
of MMSE-C. Patients with sDAT manifested a significantly 
higher score on the CES-D scale, compared to control 
subjects (mean + SD; control: 8.30 + 4.97; slow progressing: 
15.00 + 9.93, p = 0.08; fast progressing: 14.40 + 6.26, p = 
0.03). These values did not change significantly in any of the 
groups at 6 months, 12 months or 18 months into the study 
(data not shown). POMS scores were higher, albeit not 
significantly, in patients with Fast Progression sDAT at entry 
(mean + SD: 28.33 + 23.29), compared to their cohorts with 
Slow progression sDAT symptoms (16.14 + 31.56) and 
control subjects (14.14 + 13.21). There was a notable lack of 
remarkable changes in CES-D and POMS among the groups 
across time. 
 
It was also notable that the percent of CD3-CD16+CD56+ 
(phenotypic signature of NK cells) was indistinguishable 
among the three groups at entry (mean % + SD, control: 
19.34 + 7.78; Slow Progression sDAT: 15.25 + 7.32; Fast 
Progression sDAT: 15.30 + 6.55), and remained comparable 
at 18 months (mean % + SD, control: 18.60 + 6.45; Slow 
Progression sDAT: 13.66 + 7.71; Fast Progression sDAT: 
18.60 + 10.21). Patients with sDAT and normal control 
subjects also did not differ along T cell immunophenotypic 
indexes of CD4/CD8 ratio, CD4+ T cells, or CD8+ T cells 
(Table 1 under supplementary material). Circulating activated 
T cells, recognized phenotypically as expressing the CD3 
moiety (CD3+) and the human leukocyte antigen Dr (Dr+), 
did not change in the group of control subjects in time (mean 
+ SD; entry: 13.90 + 13.00, 18 month: 12.70 + 8.08).  
However, the data showed a trend toward an increase in 
CD3+Dr+ in patients with sDAT (mean + SD; Slow 
Progression sDAT entry: 10.75 + 4.95; 18 month: 14.13 + 
5.87, p = ns; Fast Progression sDAT entry: 13.10 +7.89; 18 
month: 16.40 + 9.50, p=ns).  
 
The change in CD3+Dr+ between entry and 18 month was 
not correlated with the change in MMSE score in patients 
with sDAT (r = 0.012), but it was significantly inversely 
correlated with the change in time in the response of NK 
cytotoxic activity to cortisol modulation (r = -0.454, p<0.05).  
This inverse relationship was stronger in the patients with 
Fast progression sDAT with 1.5 greater proportion of the 
variance accounted for by this correlative relationship, 
compared to patients with Slow progression sDAT.  
CD3+Dr+ T cells often express also the transferrin receptor, 
CD71, and the Δ chain of the IL-2 receptor, CD25. [15] These 
cells are endowed with the capacity toward end-stage 
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maturation of T cells into mature memory cells capable of a 
TH1 or a TH2 pattern of cytokine production.  CD25+ T cells 
are important regulatory cells (e.g., CD4+CD25+FoxP3+) of 
the cellular arm of immune surveillance. Our data suggest a 
trend toward an increase in Tregs in patients with sDAT. This 
observation is novel and critical, since the functional role of 
Tregs is to suppress activation of effector T cells. If 
confirmed, this observation will shed light into the regulatory 
mechanisms of immune surveillance in patients with sDAT, 
and provide a better understanding of the clinical 
immunopathology of sDAT. 
 
Our observations are also congruent with a putative 
intermediary role played by Tregs in sDAT. Cortisol in 
particular up-regulates IL-10 [16], a key regulatory cytokine 
of NK cells and of Tregs.  At the molecular level, this 
regulatory process appears to be accounted for by the 
glucocorticoids-induced tumor necrosis factor receptor 
(TNFr) family-related gene (GITR) on Tregs. [17] The 
functional role of GITR in Tregs is likely to be associated 
with the signaling pathways involving the family of 
suppressors of cytokine signaling (SOCS). [18] The 
observation that IL-10 induces the expression of SOCS-1 and 
SOCS-3, an outcome that is dependent upon activation of the 
signal transducer and activator of transcription (STAT) 3 by 
chain 1 of the IL-10 receptor (IL-10R1), and is associated 
with the inhibition of IFN γ signaling [15] confirms the 
putative role of these pathways in the cortisol modulation of 
NK, and other cellular immune functions. The next frontier in 
cellular immunology research in sDAT will include the 
characterization of the role of IL-10 and cortisol directly on 
the SOCS pathway in NK and other T cell sub-populations.   
 
In other studies, we have discussed the concept of evidence-
based translational research and practice as the 2-way transfer 
between fundamental investigative work and the clinical 
endeavor as it pertains directly to patients with Alzheimer’s 
disease. We have noted that laboratory evidence, such as the 
reliable assessment of the β amyloid protein in salivary 
samples [19], and psycho-cognitive and emotional assessment 
of fit and adaptation [20] must contribute to a well-rounded 
evidence-based clinical decision-making process. 
 
Here, we propose the workable hypothesis that during 
progression of sDAT, characteristic shifts occur in the reading 
frame of the genome, therefore obfuscating normally coding 
DNA, and exposing otherwise non-coding DNA. That is to 
say, significant changes in the molecular epigenetic structure 
of the genome are likely to occur during progression of 
sDAT, which may lead to marked alterations in the molecular 
cartography inherent to a variety of cells, tissues and organs 
of the patient, including cells of the immune system.  
Consequently, Tregs and other T cell subpopulations, and NK 
cells, may be expected to find their capacity to respond to and 
to be modulated by neuroendocrine products progressively 
adulterated as the disease progresses. Further molecular 
research should be directed at confirming and expanding 
these observations, and at testing this fundamental hypothesis. 
Confirmatory studies of this type will uncover new avenues 
of molecular medicine interventions for patients with 
Alzheimer’s disease grounded on translational evidence-
based epigenetics. 
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Supplementary material 
 
Entry 18 month 
Sample 
number 
CD4+ CD3+Dr+ CD8+ CD4/CD8 CD4+ CD3+Dr+ CD8+ CD4/CD8 
Control         
1 45 2 18 2.5 46 4 16 2.87 
2 42 8 21 2.0 41 16 22 1.86 
3 41 13 26 1.06 37 10 27 1.4 
4 43 - 32 1.3 38 23 32 1.2 
5 50 11 21 2.3 53 9 20 2.6 
6 50 8 30 1.6 43 15 20 2.15 
7 54 4 27 1.9 52 2 28 1.8 
8 44 14 22 2.0 36 17 28 1.29 
9 - - - - 36 26 37 0.97 
10 45 9 21 2.1 47 5 20 2.03 
Mean 42.60 13.90 26.60 1.86 42.90 12.70 25.00 1.82 
SD 11.51 13.00 8.75 0.46 6.40 8.08 6.50 0.62 
Slow P1  
11 38 9 39 0.98 35 9 28 1.25 
12 44 10 38 1.15 45 11 33 1.4 
13 56 4 16 3.5 57 25 18 3.1 
14 37 15 19 1.95 38 15 22 1.73 
15 64 4 15 4.2 57 13 13 4.38 
16 50 15 17 2.9 52 16 19 2.7 
17 43 17 23 1.86 58 18 22 2.6 
18 48 12 23 2.01 50 6 27 1.85 
Mean 47.50 10.75 23.75 2.32 49.00 14.13 22.75 2.38 
SD 9.13 4.95 9.57 1.13 8.88 5.87 6.36 1.04 
Fast P2  
19 44 10 21 2.0 46 14 20 2.02 
20 29 9 26 1.1 27 20 21 1.29 
21 44 25 28 1.57 44 38 30 1.47 
22 52 25 28 1.9 45 10 29 1.55 
23 50 11 24 2.0 45 5 23 1.96 
24 40 18 23 1.07 42 14 22 1.90 
25 42 1 27 1.5 52 14 18 2.9 
26 56 16 16 3.5 42 13 17 2.47 
27 42 4 24 1.75 40 10 23 1.7 
28 62 14 9 6.9 54 26 8 6.8 
Mean 46.10 13.10 22.60 2.33 43.70 16.40 21.10 2.41 
SD 9.27 7.89 6.00 1.74 7.32 9.50 6.23 1.62 
Table 1: Immunophenotypic characterization of the subjects at entry and 18 months (given as % of circulating lymphocytes, 
identified by the CD45+CD14- LeukoGate gate) 1: Slow progression sDAT; 2: Fast progression sDAT 
 
 
Baseline Cortisol (10-6M) hrIL-2 (650 IU/ml) 
 Mean 
(lytic units) 
+SEM Mean 
(lytic units) 
+SEM Mean  
(lytic units) 
+SEM 
Control 32.51 6.5 23.92 3.83 75.83 19.41 
Slow Progressing sDAT1 23.26 3.31 15.89 2.38 79.39 28.50 
p vs. control 0.24  0.10  0.92  
Fast Progressing sDAT1 21.13 3.40 15.33 2.60 38.46 6.82 
p vs. control 0.14  0.08  0.09  
Table 2: Modulation of NK Activity (at entry) (1: as determined by drop in MMSE score at 18 months) 
 
 
 
 
 
